Infantile Parkinsonism-Dystonia

⚙

Pathophysiology

3

Dopamine Transporter Loss of Function

Biallelic loss-of-function variants in SLC6A3 produce a mutant dopamine transporter (DAT) with multifaceted dysfunction: reduced transporter activity, impaired dopamine binding, reduced cell-surface expression, and aberrant posttranslational modification with impaired glycosylation. The net effect is a profound deficit in presynaptic reuptake of dopamine from the synaptic cleft.

Midbrain dopaminergic neuron CL:0000700

SLC6A3 hgnc:11049

Dopamine transport GO:0015872 ↓ DECREASED Dopamine reuptake at the synapse GO:0051583 ↓ DECREASED

Downstream

Dysregulated Synaptic Dopamine Homeostasis

Show evidence (2 references)

PMID:37443770 SUPPORT Human Clinical

"Amino acid substitutions result in mutant proteins with impaired dopamine transporter function due to reduced transporter activity, impaired dopamine binding, reduced cell-surface expression, and aberrant posttranslational protein modification with impaired glycosylation."

Defines the molecular consequences of pathogenic SLC6A3 variants on DAT function.

PMID:34002696 SUPPORT In Vitro

"Common to DTDS-linked DAT variants is a multifaceted loss of DAT function, which includes impaired transporter activity and decreased expression"

In vitro and structural work confirms loss of DAT activity and expression as the shared molecular defect in DTDS.

Dysregulated Synaptic Dopamine Homeostasis

Impaired DAT-mediated reuptake reduces dopamine clearance, raising extracellular synaptic dopamine and increasing dopamine turnover. This is reflected biochemically as elevated cerebrospinal fluid homovanillic acid (HVA, a dopamine catabolite) with normal 5-hydroxyindoleacetic acid (5-HIAA), yielding a raised HVA:5-HIAA ratio, and by absent or markedly reduced presynaptic DAT tracer uptake in the basal ganglia on DaTscan.

Midbrain dopaminergic neuron CL:0000700

Regulation of dopamine secretion GO:0014059 ↕ DYSREGULATED

Downstream

Dopaminergic Neurodegeneration and Nigrostriatal Dysfunction

Show evidence (2 references)

PMID:34011628 SUPPORT Human Clinical

"Patients present with early infantile hyperkinesia, severe progressive childhood parkinsonism, and raised cerebrospinal fluid dopamine metabolites."

Documents the raised CSF dopamine metabolites that reflect dysregulated synaptic dopamine homeostasis.

PMID:34002696 SUPPORT In Vitro

"Increased levels of HVA might reflect increased DA turnover promoted by higher extracellular DA levels."

Explains the mechanistic link between loss of reuptake, increased extracellular dopamine, increased turnover, and elevated HVA.

Dopaminergic Neurodegeneration and Nigrostriatal Dysfunction

Excess synaptic dopamine and impaired handling lead to dopamine toxicity, oxidative/carbonyl stress, TNF-alpha-mediated inflammation, and apoptotic neurodegeneration of midbrain dopaminergic neurons, demonstrated in patient iPSC-derived midbrain dopaminergic neurons and in the DAT knockout mouse, which recapitulates tremor, bradykinesia, and premature death. The substantia nigra and striatum are the principal affected structures of the nigrostriatal system, and their dysfunction underlies the progressive parkinsonism-dystonia phenotype.

Midbrain dopaminergic neuron CL:0000700

Neuron apoptotic process GO:0051402 ↑ INCREASED Neuroinflammatory response GO:0150076 ↑ INCREASED

Show evidence (2 references)

PMID:34011628 SUPPORT In Vitro

"we generated a midbrain dopaminergic (mDA) neuron model of DTDS that exhibited marked impairment of DAT activity, apoptotic neurodegeneration associated with TNFα-mediated inflammation, and dopamine toxicity."

Patient iPSC-derived neurons demonstrate apoptotic neurodegeneration, inflammation, and dopamine toxicity downstream of DAT loss.

PMID:34011628 SUPPORT Model Organism

"we used the knockout mouse model of DTDS that recapitulates human disease, exhibiting parkinsonism features, including tremor, bradykinesia, and premature death."

The DAT knockout mouse recapitulates the parkinsonian motor phenotype, supporting the causal link between transporter loss and nigrostriatal dysfunction.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

12

Digestive 1

Feeding Difficulties Feeding difficulties HP:0011968

Onset: INFANTILE

Show evidence (1 reference)

PMID:28749637 SUPPORT Human Clinical

"Infants typically manifest nonspecific findings (irritability, feeding difficulties, axial hypotonia, and/or delayed motor development)"

GeneReviews lists feeding difficulties as an early infantile finding.

Musculoskeletal 2

Rigidity Rigidity HP:0002063

Show evidence (1 reference)

PMID:28749637 SUPPORT Human Clinical

"bradykinesia (progressing to akinesia), dystonic posturing, distal tremor, rigidity, and reduced facial expression."

GeneReviews lists rigidity among the parkinsonian features.

Axial Hypotonia Hypotonia HP:0001252

Onset: INFANTILE

Show evidence (1 reference)

PMID:28749637 SUPPORT Human Clinical

"Infants typically manifest nonspecific findings (irritability, feeding difficulties, axial hypotonia, and/or delayed motor development)"

GeneReviews lists axial hypotonia as an early infantile finding.

Nervous System 7

Parkinsonism-Dystonia Parkinsonism HP:0001300

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:28749637 SUPPORT Human Clinical

"Over time, affected individuals develop parkinsonism-dystonia characterized by bradykinesia (progressing to akinesia), dystonic posturing, distal tremor, rigidity, and reduced facial expression."

GeneReviews describes the evolution to parkinsonism-dystonia as the core phenotype.

Dystonia Dystonia HP:0001332

Show evidence (1 reference)

PMID:28749637 SUPPORT Human Clinical

"Episodic status dystonicus, exacerbations of dystonia, and secondary orthopedic, gastrointestinal, and respiratory complications are common."

GeneReviews documents dystonia and status dystonicus as common features.

Bradykinesia Bradykinesia HP:0002067

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:28749637 SUPPORT Human Clinical

"affected individuals develop parkinsonism-dystonia characterized by bradykinesia (progressing to akinesia), dystonic posturing, distal tremor, rigidity, and reduced facial expression."

GeneReviews lists bradykinesia progressing to akinesia as a defining feature.

Tremor Tremor HP:0001337

Show evidence (1 reference)

PMID:34011628 PARTIAL Human Clinical

"Patients present with early infantile hyperkinesia, severe progressive childhood parkinsonism, and raised cerebrospinal fluid dopamine metabolites."

Supports progressive parkinsonism (which includes tremor) as a clinical feature; tremor is detailed in the GeneReviews parkinsonism description.

Hyperkinetic Movement Disorder Chorea HP:0002072

Show evidence (1 reference)

PMID:28749637 SUPPORT Human Clinical

"followed by a hyperkinetic movement disorder (with features of chorea, dystonia, ballismus, orolingual dyskinesia)."

GeneReviews documents the early hyperkinetic phase including chorea.

Delayed Motor Development Delayed gross motor development HP:0002194

Show evidence (1 reference)

PMID:28749637 SUPPORT Human Clinical

"Infants typically manifest nonspecific findings (irritability, feeding difficulties, axial hypotonia, and/or delayed motor development)"

GeneReviews lists delayed motor development as an early feature.

Irritability Irritability HP:0000737

Onset: INFANTILE

Show evidence (1 reference)

PMID:28749637 SUPPORT Human Clinical

"Infants typically manifest nonspecific findings (irritability, feeding difficulties, axial hypotonia, and/or delayed motor development)"

GeneReviews lists irritability as an early infantile finding.

Other 2

Oculogyric Crisis Oculogyric crisis HP:0010553

Show evidence (1 reference)

PMID:40291937 PARTIAL Human Clinical

"These rare syndromes manifest with movement disorders and neuropsychiatric symptoms."

Comparative review of monoamine transport disorders (including DTDS) supports the movement-disorder spectrum; oculogyric crises are documented in DTDS case literature.

Decreased Facial Expression Decreased facial expression HP:0004673

Show evidence (1 reference)

PMID:28749637 SUPPORT Human Clinical

"bradykinesia (progressing to akinesia), dystonic posturing, distal tremor, rigidity, and reduced facial expression."

GeneReviews lists reduced facial expression as a parkinsonian feature.

🧬

Genetic Associations

1

SLC6A3 (Biallelic loss-of-function variants)

Gene: SLC6A3 hgnc:11049

Show evidence (2 references)

PMID:37443770 SUPPORT Human Clinical

"Infantile parkinsonism-dystonia due to dopamine transporter deficiency syndrome (DTDS) is an ultrarare childhood movement disorder caused by biallelic loss-of-function mutations in the SLC6A3 gene."

Review establishes biallelic loss-of-function SLC6A3 variants as the cause of infantile parkinsonism-dystonia / DTDS.

PMID:28749637 SUPPORT Human Clinical

"In most individuals reported to date, SLC6A3-related DTDS is caused by biallelic loss-of-function pathogenic variants and inherited in an autosomal recessive manner."

GeneReviews confirms autosomal recessive inheritance of biallelic SLC6A3 loss-of-function variants.

💊

Medical Actions

8

Supportive and Symptomatic Care

Action: supportive care MAXO:0000950

Standard pharmacotherapy has limited efficacy in DTDS. Supportive management includes nutrition and feeding support, physical therapy to reduce contracture and fracture risk, management of respiratory infections, and treatment of pain that can exacerbate movement disorders. Care is largely supportive given the absence of disease-modifying therapy.

Show evidence (1 reference)

PMID:28749637 SUPPORT Human Clinical

"Supportive management and developmental support includes: nutrition management and feeding support for oral feeding issues"

GeneReviews describes supportive management as a mainstay of care.

Tetrabenazine

Action: Pharmacotherapy NCIT:C15986

Agent: tetrabenazine CHEBI:9467

Tetrabenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor, is used to control chorea and dyskinesia in the early hyperkinetic stages of disease.

Show evidence (1 reference)

PMID:28749637 SUPPORT Human Clinical

"Treatment to control chorea and dyskinesia in early stages of the disease includes tetrabenazine and benzodiazepines."

GeneReviews recommends tetrabenazine for early chorea/dyskinesia.

Benzodiazepines

Action: Pharmacotherapy NCIT:C15986

Agent: benzodiazepine NCIT:C1012

Benzodiazepines are used to control chorea and dyskinesia in early disease and for exacerbations of dystonia or status dystonicus.

Show evidence (1 reference)

PMID:28749637 SUPPORT Human Clinical

"chloral hydrate and benzodiazepines for exacerbations of dystonia or status dystonicus."

GeneReviews recommends benzodiazepines for dystonic exacerbations.

Dopamine Agonist Therapy

Action: Pharmacotherapy NCIT:C15986

Agent: pramipexole CHEBI:8356 dopamine agonist NCIT:C66884

Dopamine agonists pramipexole and ropinirole are used as first-line agents for dystonia, which is more difficult to control than chorea. The older ergot dopamine agonists bromocriptine and pergolide are generally avoided because of fibrosis risk.

Show evidence (2 references)

PMID:28749637 SUPPORT Human Clinical

"Dystonia is more difficult to control, and treatment often includes the dopamine agonists pramipexole and ropinirole as first-line agents"

GeneReviews recommends dopamine agonists as first-line for dystonia.

PMID:28749637 SUPPORT Human Clinical

"Although the dopamine agonists bromocriptine and pergolide could be considered, the associated increased risk of pulmonary, retroperitoneal, and pericardial fibrosis makes them less desirable than the newer dopamine agonists."

GeneReviews Agents/Circumstances to Avoid: older ergot dopamine agonists carry fibrosis risk and are less desirable.

Levodopa

Action: Pharmacotherapy NCIT:C15986

Agent: levodopa CHEBI:15765

Levodopa is generally ineffective in DTDS, with limited or no response reported, consistent with the presynaptic dopamine-handling defect rather than a dopamine synthesis deficiency.

Show evidence (1 reference)

PMID:40291937 PARTIAL Human Clinical

"DTDS results from a mutation in the SLC6A3 gene affecting dopamine reuptake"

The defect is in dopamine reuptake (not synthesis), the mechanistic basis for poor levodopa response; limited/no levodopa response is documented in DTDS reviews.

Physical Therapy

Action: Physical Therapy NCIT:C15302

Regular physical therapy and medical management of tone are used to reduce the risk of contractures and fractures.

Show evidence (1 reference)

PMID:28749637 SUPPORT Human Clinical

"medical management of tone issues and regular physical therapy to reduce the risk of contractures and fractures"

GeneReviews recommends regular physical therapy.

Genetic Counseling

Action: Genetic Counseling NCIT:C15240

Genetic counseling is offered given autosomal recessive inheritance; once the SLC6A3 variants are identified in a family member, prenatal and preimplantation genetic testing are possible.

Show evidence (1 reference)

PMID:28749637 SUPPORT Human Clinical

"Once the SLC6A3 pathogenic variant(s) have been identified in an affected family member, prenatal and preimplantation genetic testing are possible."

GeneReviews supports genetic counseling and family-based testing.

Gene Therapy (Investigational)

Action: gene therapy MAXO:0001001

AAV- and lentivirus-mediated gene therapy delivering wild-type SLC6A3 is in preclinical development. In patient iPSC-derived neurons and DAT knockout mice, SLC6A3 gene transfer restored DAT activity, prevented neurodegeneration, and improved motor phenotype and survival; targeted midbrain delivery avoided off-target toxicity. This approach is investigational and not yet an approved therapy.

Show evidence (2 references)

PMID:34011628 SUPPORT Model Organism

"These were avoided with stereotactic delivery of AAV2.SLC6A3 gene therapy targeted to the midbrain of adult knockout mice, which rescued both motor phenotype and neurodegeneration, suggesting that targeted AAV gene therapy might be effective for patients with DTDS."

Preclinical evidence that targeted AAV2.SLC6A3 gene therapy rescues the DTDS phenotype in the mouse model.

PMID:37147851 SUPPORT Human Clinical

"Here, we review recent advances in gene therapy, focused on the targeted delivery of dopaminergic genes for Parkinson's disease and the primary neurotransmitter disorders, AADC deficiency and dopamine transporter deficiency syndrome (DTDS)."

Review frames dopaminergic gene therapy, including for DTDS, as an emerging therapeutic strategy.

🔬

Biochemical Markers

1

Raised CSF HVA:5-HIAA Ratio (Positive)

Show evidence (1 reference)

PMID:34011628 SUPPORT Human Clinical

"Patients present with early infantile hyperkinesia, severe progressive childhood parkinsonism, and raised cerebrospinal fluid dopamine metabolites."

Documents raised CSF dopamine metabolites, the basis for the elevated HVA:5-HIAA ratio used diagnostically.

{ }

Source YAML

click to show

name: Infantile Parkinsonism-Dystonia
creation_date: "2026-06-04T12:00:00Z"
category: Mendelian
parents:
- Movement Disorder
- Parkinsonian Disorder
- Combined Dystonia
- Inborn Disorder of Neurotransmitter Metabolism
disease_term:
  preferred_term: Infantile parkinsonism-dystonia
  term:
    id: MONDO:0013150
    label: parkinsonism-dystonia, infantile
description: >-
  Infantile parkinsonism-dystonia, also known as dopamine transporter deficiency
  syndrome (DTDS), is an ultrarare autosomal recessive movement disorder caused by
  biallelic loss-of-function variants in SLC6A3, which encodes the presynaptic
  dopamine transporter (DAT). Impaired dopamine reuptake leads to a continuum that
  ranges from classic early-onset disease (by age 6 months) presenting with
  irritability, feeding difficulties, axial hypotonia, and a hyperkinetic movement
  disorder that evolves into severe progressive parkinsonism-dystonia, to atypical
  later-onset forms. A characteristic biochemical signature is a raised cerebrospinal
  fluid homovanillic acid (HVA) to 5-hydroxyindoleacetic acid (5-HIAA) ratio with
  absent/markedly reduced striatal DAT uptake on DaTscan. Standard dopaminergic
  pharmacotherapy is largely ineffective; care is supportive, and gene therapy and
  pharmacochaperone approaches are in preclinical development.
references:
- reference: PMID:28749637
  title: "SLC6A3-Related Dopamine Transporter Deficiency Syndrome."
  tags:
  - GeneReviews
synonyms:
- Dopamine transporter deficiency syndrome
- DTDS
- SLC6A3-related dopamine transporter deficiency syndrome
- Parkinsonism-dystonia, infantile, 1
- PKDYS
genetic:
- name: SLC6A3
  association: Biallelic loss-of-function variants
  presence: Positive
  gene_term:
    preferred_term: SLC6A3
    term:
      id: hgnc:11049
      label: SLC6A3
  notes: >-
    DTDS is most commonly caused by biallelic loss-of-function pathogenic variants
    in SLC6A3 (encoding the dopamine transporter, DAT) inherited in an autosomal
    recessive manner. Reported variants include protein-truncating changes (nonsense,
    splice-site, deletions) and missense substitutions. A single autosomal dominant
    case caused by a heterozygous dominant-negative SLC6A3 variant has been reported.
  evidence:
  - reference: PMID:37443770
    reference_title: "Dopamine Transporter Deficiency Syndrome (DTDS): Expanding the Clinical Phenotype and Precision Medicine Approaches."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Infantile parkinsonism-dystonia due to dopamine transporter deficiency syndrome
      (DTDS) is an ultrarare childhood movement disorder caused by biallelic
      loss-of-function mutations in the SLC6A3 gene.
    explanation: >-
      Review establishes biallelic loss-of-function SLC6A3 variants as the cause of
      infantile parkinsonism-dystonia / DTDS.
  - reference: PMID:28749637
    reference_title: "SLC6A3-Related Dopamine Transporter Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In most individuals reported to date, SLC6A3-related DTDS is caused by biallelic
      loss-of-function pathogenic variants and inherited in an autosomal recessive manner.
    explanation: >-
      GeneReviews confirms autosomal recessive inheritance of biallelic SLC6A3
      loss-of-function variants.
pathophysiology:
- name: Dopamine Transporter Loss of Function
  description: >-
    Biallelic loss-of-function variants in SLC6A3 produce a mutant dopamine
    transporter (DAT) with multifaceted dysfunction: reduced transporter activity,
    impaired dopamine binding, reduced cell-surface expression, and aberrant
    posttranslational modification with impaired glycosylation. The net effect is a
    profound deficit in presynaptic reuptake of dopamine from the synaptic cleft.
  genes:
  - preferred_term: SLC6A3
    term:
      id: hgnc:11049
      label: SLC6A3
  cell_types:
  - preferred_term: Midbrain dopaminergic neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: Dopamine transport
    term:
      id: GO:0015872
      label: dopamine transport
    modifier: DECREASED
  - preferred_term: Dopamine reuptake at the synapse
    term:
      id: GO:0051583
      label: dopamine uptake involved in synaptic transmission
    modifier: DECREASED
  downstream:
  - target: Dysregulated Synaptic Dopamine Homeostasis
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:37443770
    reference_title: "Dopamine Transporter Deficiency Syndrome (DTDS): Expanding the Clinical Phenotype and Precision Medicine Approaches."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Amino acid substitutions result in mutant proteins with impaired dopamine
      transporter function due to reduced transporter activity, impaired dopamine
      binding, reduced cell-surface expression, and aberrant posttranslational protein
      modification with impaired glycosylation.
    explanation: >-
      Defines the molecular consequences of pathogenic SLC6A3 variants on DAT function.
  - reference: PMID:34002696
    reference_title: "Psychomotor impairments and therapeutic implications revealed by a mutation associated with infantile Parkinsonism-Dystonia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Common to DTDS-linked DAT variants is a multifaceted loss of DAT function, which
      includes impaired transporter activity and decreased expression
    explanation: >-
      In vitro and structural work confirms loss of DAT activity and expression as the
      shared molecular defect in DTDS.
- name: Dysregulated Synaptic Dopamine Homeostasis
  description: >-
    Impaired DAT-mediated reuptake reduces dopamine clearance, raising extracellular
    synaptic dopamine and increasing dopamine turnover. This is reflected biochemically
    as elevated cerebrospinal fluid homovanillic acid (HVA, a dopamine catabolite) with
    normal 5-hydroxyindoleacetic acid (5-HIAA), yielding a raised HVA:5-HIAA ratio, and
    by absent or markedly reduced presynaptic DAT tracer uptake in the basal ganglia on
    DaTscan.
  cell_types:
  - preferred_term: Midbrain dopaminergic neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: Regulation of dopamine secretion
    term:
      id: GO:0014059
      label: regulation of dopamine secretion
    modifier: DYSREGULATED
  downstream:
  - target: Dopaminergic Neurodegeneration and Nigrostriatal Dysfunction
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:34011628
    reference_title: "Gene therapy restores dopamine transporter expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients present with early infantile hyperkinesia, severe progressive childhood
      parkinsonism, and raised cerebrospinal fluid dopamine metabolites.
    explanation: >-
      Documents the raised CSF dopamine metabolites that reflect dysregulated synaptic
      dopamine homeostasis.
  - reference: PMID:34002696
    reference_title: "Psychomotor impairments and therapeutic implications revealed by a mutation associated with infantile Parkinsonism-Dystonia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Increased levels of HVA might reflect increased DA turnover promoted by higher
      extracellular DA levels.
    explanation: >-
      Explains the mechanistic link between loss of reuptake, increased extracellular
      dopamine, increased turnover, and elevated HVA.
- name: Dopaminergic Neurodegeneration and Nigrostriatal Dysfunction
  description: >-
    Excess synaptic dopamine and impaired handling lead to dopamine toxicity,
    oxidative/carbonyl stress, TNF-alpha-mediated inflammation, and apoptotic
    neurodegeneration of midbrain dopaminergic neurons, demonstrated in patient
    iPSC-derived midbrain dopaminergic neurons and in the DAT knockout mouse, which
    recapitulates tremor, bradykinesia, and premature death. The substantia nigra and
    striatum are the principal affected structures of the nigrostriatal system, and
    their dysfunction underlies the progressive parkinsonism-dystonia phenotype.
  cell_types:
  - preferred_term: Midbrain dopaminergic neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: Neuron apoptotic process
    term:
      id: GO:0051402
      label: neuron apoptotic process
    modifier: INCREASED
  - preferred_term: Neuroinflammatory response
    term:
      id: GO:0150076
      label: neuroinflammatory response
    modifier: INCREASED
  evidence:
  - reference: PMID:34011628
    reference_title: "Gene therapy restores dopamine transporter expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      we generated a midbrain dopaminergic (mDA) neuron model of DTDS that exhibited
      marked impairment of DAT activity, apoptotic neurodegeneration associated with
      TNFα-mediated inflammation, and dopamine toxicity.
    explanation: >-
      Patient iPSC-derived neurons demonstrate apoptotic neurodegeneration, inflammation,
      and dopamine toxicity downstream of DAT loss.
  - reference: PMID:34011628
    reference_title: "Gene therapy restores dopamine transporter expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      we used the knockout mouse model of DTDS that recapitulates human disease,
      exhibiting parkinsonism features, including tremor, bradykinesia, and premature death.
    explanation: >-
      The DAT knockout mouse recapitulates the parkinsonian motor phenotype, supporting
      the causal link between transporter loss and nigrostriatal dysfunction.
phenotypes:
- name: Parkinsonism-Dystonia
  description: >-
    Affected individuals develop a combined parkinsonism-dystonia characterized by
    bradykinesia (progressing to akinesia), dystonic posturing, distal tremor,
    rigidity, and reduced facial expression.
  phenotype_term:
    preferred_term: Parkinsonism
    term:
      id: HP:0001300
      label: Parkinsonism
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:28749637
    reference_title: "SLC6A3-Related Dopamine Transporter Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Over time, affected individuals develop parkinsonism-dystonia characterized by
      bradykinesia (progressing to akinesia), dystonic posturing, distal tremor,
      rigidity, and reduced facial expression.
    explanation: >-
      GeneReviews describes the evolution to parkinsonism-dystonia as the core phenotype.
- name: Dystonia
  description: >-
    Dystonia with dystonic posturing is a hallmark feature; it is difficult to control
    and may present as exacerbations or episodic status dystonicus.
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:28749637
    reference_title: "SLC6A3-Related Dopamine Transporter Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Episodic status dystonicus, exacerbations of dystonia, and secondary orthopedic,
      gastrointestinal, and respiratory complications are common.
    explanation: >-
      GeneReviews documents dystonia and status dystonicus as common features.
- name: Bradykinesia
  description: >-
    Bradykinesia is a core parkinsonian feature that progresses to akinesia, with
    limitation of voluntary movements leading to severe motor delay.
  phenotype_term:
    preferred_term: Bradykinesia
    term:
      id: HP:0002067
      label: Bradykinesia
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:28749637
    reference_title: "SLC6A3-Related Dopamine Transporter Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      affected individuals develop parkinsonism-dystonia characterized by bradykinesia
      (progressing to akinesia), dystonic posturing, distal tremor, rigidity, and reduced
      facial expression.
    explanation: >-
      GeneReviews lists bradykinesia progressing to akinesia as a defining feature.
- name: Rigidity
  description: Rigidity is a component of the evolving parkinsonism-dystonia phenotype.
  phenotype_term:
    preferred_term: Rigidity
    term:
      id: HP:0002063
      label: Rigidity
  evidence:
  - reference: PMID:28749637
    reference_title: "SLC6A3-Related Dopamine Transporter Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      bradykinesia (progressing to akinesia), dystonic posturing, distal tremor,
      rigidity, and reduced facial expression.
    explanation: GeneReviews lists rigidity among the parkinsonian features.
- name: Tremor
  description: Distal tremor is a feature of the parkinsonian phase.
  phenotype_term:
    preferred_term: Distal tremor
    term:
      id: HP:0001337
      label: Tremor
  evidence:
  - reference: PMID:34011628
    reference_title: "Gene therapy restores dopamine transporter expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients present with early infantile hyperkinesia, severe progressive childhood
      parkinsonism, and raised cerebrospinal fluid dopamine metabolites.
    explanation: >-
      Supports progressive parkinsonism (which includes tremor) as a clinical feature;
      tremor is detailed in the GeneReviews parkinsonism description.
- name: Hyperkinetic Movement Disorder
  description: >-
    Early disease manifests with a hyperkinetic movement disorder, with features of
    chorea, dystonia, ballismus, and orolingual dyskinesia, before evolution to
    parkinsonism-dystonia.
  phenotype_term:
    preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
  evidence:
  - reference: PMID:28749637
    reference_title: "SLC6A3-Related Dopamine Transporter Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      followed by a hyperkinetic movement disorder (with features of chorea, dystonia,
      ballismus, orolingual dyskinesia).
    explanation: >-
      GeneReviews documents the early hyperkinetic phase including chorea.
- name: Oculogyric Crisis
  description: >-
    Oculogyric crises (episodic conjugate upward deviation of the eyes) are a
    characteristic eye-movement feature reported in infantile parkinsonism-dystonia and
    related monoamine neurotransmitter disorders.
  phenotype_term:
    preferred_term: Oculogyric crisis
    term:
      id: HP:0010553
      label: Oculogyric crisis
  evidence:
  - reference: PMID:40291937
    reference_title: "A comparative exploration of monoamine neurotransmitter transport disorders: mechanisms, clinical manifestations, and therapeutic approaches."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These rare syndromes manifest with movement disorders and neuropsychiatric symptoms.
    explanation: >-
      Comparative review of monoamine transport disorders (including DTDS) supports the
      movement-disorder spectrum; oculogyric crises are documented in DTDS case literature.
- name: Axial Hypotonia
  description: >-
    Axial (truncal) hypotonia is among the early nonspecific infantile findings.
  phenotype_term:
    preferred_term: Axial hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
    onset:
      onset_category: INFANTILE
  evidence:
  - reference: PMID:28749637
    reference_title: "SLC6A3-Related Dopamine Transporter Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Infants typically manifest nonspecific findings (irritability, feeding difficulties,
      axial hypotonia, and/or delayed motor development)
    explanation: GeneReviews lists axial hypotonia as an early infantile finding.
- name: Delayed Motor Development
  description: >-
    Delayed motor development is an early feature; limitation of voluntary movements
    later leads to severe motor delay.
  phenotype_term:
    preferred_term: Delayed gross motor development
    term:
      id: HP:0002194
      label: Delayed gross motor development
  evidence:
  - reference: PMID:28749637
    reference_title: "SLC6A3-Related Dopamine Transporter Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Infants typically manifest nonspecific findings (irritability, feeding difficulties,
      axial hypotonia, and/or delayed motor development)
    explanation: GeneReviews lists delayed motor development as an early feature.
- name: Feeding Difficulties
  description: >-
    Feeding difficulties are among the early nonspecific infantile findings; oral
    feeding issues often require nutrition and feeding support.
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
    onset:
      onset_category: INFANTILE
  evidence:
  - reference: PMID:28749637
    reference_title: "SLC6A3-Related Dopamine Transporter Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Infants typically manifest nonspecific findings (irritability, feeding difficulties,
      axial hypotonia, and/or delayed motor development)
    explanation: GeneReviews lists feeding difficulties as an early infantile finding.
- name: Irritability
  description: Irritability is one of the earliest nonspecific infantile findings.
  phenotype_term:
    preferred_term: Irritability
    term:
      id: HP:0000737
      label: Irritability
    onset:
      onset_category: INFANTILE
  evidence:
  - reference: PMID:28749637
    reference_title: "SLC6A3-Related Dopamine Transporter Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Infants typically manifest nonspecific findings (irritability, feeding difficulties,
      axial hypotonia, and/or delayed motor development)
    explanation: GeneReviews lists irritability as an early infantile finding.
- name: Decreased Facial Expression
  description: >-
    Reduced facial expression (hypomimia) accompanies the parkinsonian phase.
  phenotype_term:
    preferred_term: Reduced facial expression
    term:
      id: HP:0004673
      label: Decreased facial expression
  evidence:
  - reference: PMID:28749637
    reference_title: "SLC6A3-Related Dopamine Transporter Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      bradykinesia (progressing to akinesia), dystonic posturing, distal tremor,
      rigidity, and reduced facial expression.
    explanation: GeneReviews lists reduced facial expression as a parkinsonian feature.
biochemical:
- name: Raised CSF HVA:5-HIAA Ratio
  presence: Positive
  notes: >-
    A characteristic diagnostic biochemical signature is raised cerebrospinal fluid
    homovanillic acid (HVA, a dopamine metabolite) with normal 5-hydroxyindoleacetic
    acid (5-HIAA), producing an elevated HVA:5-HIAA ratio that reflects increased
    dopamine turnover from impaired reuptake.
  evidence:
  - reference: PMID:34011628
    reference_title: "Gene therapy restores dopamine transporter expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients present with early infantile hyperkinesia, severe progressive childhood
      parkinsonism, and raised cerebrospinal fluid dopamine metabolites.
    explanation: >-
      Documents raised CSF dopamine metabolites, the basis for the elevated HVA:5-HIAA
      ratio used diagnostically.
treatments:
- name: Supportive and Symptomatic Care
  description: >-
    Standard pharmacotherapy has limited efficacy in DTDS. Supportive management
    includes nutrition and feeding support, physical therapy to reduce contracture and
    fracture risk, management of respiratory infections, and treatment of pain that can
    exacerbate movement disorders. Care is largely supportive given the absence of
    disease-modifying therapy.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:28749637
    reference_title: "SLC6A3-Related Dopamine Transporter Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Supportive management and developmental support includes: nutrition management
      and feeding support for oral feeding issues
    explanation: >-
      GeneReviews describes supportive management as a mainstay of care.
- name: Tetrabenazine
  description: >-
    Tetrabenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor, is used to
    control chorea and dyskinesia in the early hyperkinetic stages of disease.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: tetrabenazine
      term:
        id: CHEBI:9467
        label: tetrabenazine
  evidence:
  - reference: PMID:28749637
    reference_title: "SLC6A3-Related Dopamine Transporter Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Treatment to control chorea and dyskinesia in early stages of the disease
      includes tetrabenazine and benzodiazepines.
    explanation: GeneReviews recommends tetrabenazine for early chorea/dyskinesia.
- name: Benzodiazepines
  description: >-
    Benzodiazepines are used to control chorea and dyskinesia in early disease and for
    exacerbations of dystonia or status dystonicus.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: benzodiazepine
      term:
        id: NCIT:C1012
        label: Benzodiazepine
  evidence:
  - reference: PMID:28749637
    reference_title: "SLC6A3-Related Dopamine Transporter Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      chloral hydrate and benzodiazepines for exacerbations of dystonia or status
      dystonicus.
    explanation: GeneReviews recommends benzodiazepines for dystonic exacerbations.
- name: Dopamine Agonist Therapy
  description: >-
    Dopamine agonists pramipexole and ropinirole are used as first-line agents for
    dystonia, which is more difficult to control than chorea. The older ergot dopamine
    agonists bromocriptine and pergolide are generally avoided because of fibrosis risk.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: pramipexole
      term:
        id: CHEBI:8356
        label: pramipexole
    - preferred_term: dopamine agonist
      term:
        id: NCIT:C66884
        label: Dopamine Agonist
  evidence:
  - reference: PMID:28749637
    reference_title: "SLC6A3-Related Dopamine Transporter Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Dystonia is more difficult to control, and treatment often includes the dopamine
      agonists pramipexole and ropinirole as first-line agents
    explanation: GeneReviews recommends dopamine agonists as first-line for dystonia.
  - reference: PMID:28749637
    reference_title: "SLC6A3-Related Dopamine Transporter Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although the dopamine agonists bromocriptine and pergolide could be considered,
      the associated increased risk of pulmonary, retroperitoneal, and pericardial
      fibrosis makes them less desirable than the newer dopamine agonists.
    explanation: >-
      GeneReviews Agents/Circumstances to Avoid: older ergot dopamine agonists carry
      fibrosis risk and are less desirable.
- name: Levodopa
  description: >-
    Levodopa is generally ineffective in DTDS, with limited or no response reported,
    consistent with the presynaptic dopamine-handling defect rather than a dopamine
    synthesis deficiency.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: levodopa
      term:
        id: CHEBI:15765
        label: L-dopa
  evidence:
  - reference: PMID:40291937
    reference_title: "A comparative exploration of monoamine neurotransmitter transport disorders: mechanisms, clinical manifestations, and therapeutic approaches."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      DTDS results from a mutation in the SLC6A3 gene affecting dopamine reuptake
    explanation: >-
      The defect is in dopamine reuptake (not synthesis), the mechanistic basis for poor
      levodopa response; limited/no levodopa response is documented in DTDS reviews.
- name: Physical Therapy
  description: >-
    Regular physical therapy and medical management of tone are used to reduce the risk
    of contractures and fractures.
  treatment_term:
    preferred_term: Physical Therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  evidence:
  - reference: PMID:28749637
    reference_title: "SLC6A3-Related Dopamine Transporter Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      medical management of tone issues and regular physical therapy to reduce the risk
      of contractures and fractures
    explanation: GeneReviews recommends regular physical therapy.
- name: Genetic Counseling
  description: >-
    Genetic counseling is offered given autosomal recessive inheritance; once the
    SLC6A3 variants are identified in a family member, prenatal and preimplantation
    genetic testing are possible.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:28749637
    reference_title: "SLC6A3-Related Dopamine Transporter Deficiency Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Once the SLC6A3 pathogenic variant(s) have been identified in an affected family
      member, prenatal and preimplantation genetic testing are possible.
    explanation: GeneReviews supports genetic counseling and family-based testing.
- name: Gene Therapy (Investigational)
  description: >-
    AAV- and lentivirus-mediated gene therapy delivering wild-type SLC6A3 is in
    preclinical development. In patient iPSC-derived neurons and DAT knockout mice,
    SLC6A3 gene transfer restored DAT activity, prevented neurodegeneration, and
    improved motor phenotype and survival; targeted midbrain delivery avoided off-target
    toxicity. This approach is investigational and not yet an approved therapy.
  therapeutic_modality: GENE_THERAPY
  treatment_term:
    preferred_term: gene therapy
    term:
      id: MAXO:0001001
      label: gene therapy
  evidence:
  - reference: PMID:34011628
    reference_title: "Gene therapy restores dopamine transporter expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      These were avoided with stereotactic delivery of AAV2.SLC6A3 gene therapy targeted
      to the midbrain of adult knockout mice, which rescued both motor phenotype and
      neurodegeneration, suggesting that targeted AAV gene therapy might be effective for
      patients with DTDS.
    explanation: >-
      Preclinical evidence that targeted AAV2.SLC6A3 gene therapy rescues the DTDS
      phenotype in the mouse model.
  - reference: PMID:37147851
    reference_title: "Gene Therapy for Dopamine Dyshomeostasis: From Parkinson's to Primary Neurotransmitter Diseases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we review recent advances in gene therapy, focused on the targeted delivery
      of dopaminergic genes for Parkinson's disease and the primary neurotransmitter
      disorders, AADC deficiency and dopamine transporter deficiency syndrome (DTDS).
    explanation: >-
      Review frames dopaminergic gene therapy, including for DTDS, as an emerging
      therapeutic strategy.
datasets: []

📚

References & Deep Research

References

1

PMID:28749637

SLC6A3-Related Dopamine Transporter Deficiency Syndrome.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

1. Disease Information (Overview)

Edison Scientific Literature 34 citations 2026-06-04T11:08:26.503922

1. Disease Information (Overview)

DTDS as the prototypic infantile parkinsonism–dystonia: A 2023 review explicitly states: “Infantile parkinsonism-dystonia due to dopamine transporter deficiency syndrome (DTDS) is an ultrarare childhood movement disorder caused by biallelic loss-of-function mutations in the SLC6A3 gene.” (Published Jun 2023; https://doi.org/10.3390/cells12131737). (ng2023dopaminetransporterdeficiency pages 1-2)

Newly described cause (DRD1): A 2023 report describes a proband with “severe infantile parkinsonism-dystonia…frequent oculogyric crises, dysautonomia and global neurodevelopmental impairment,” and identifies a homozygous loss-of-function DRD1 variant. (Published Mar 2023; https://doi.org/10.3390/cells12071046). (reid2023lossoffunctionvariantsin pages 1-2)

SLC18A2/PKDYS2 overlap: A 2024 PKDYS2 case report describes infantile-onset dystonia-parkinsonism due to SLC18A2 with oculogyric crises, hypotonia, and severe disability, underscoring overlap with the infantile parkinsonism-dystonia clinical space. (Published Apr 2024; https://doi.org/10.1155/2024/4767647). (kaasalainen2024novelslc18a2variant pages 1-2, kaasalainen2024novelslc18a2variant pages 2-3)

2. Etiology

2.1 Disease causal factors (primary)

Genetic (Mendelian) etiologies supported by retrieved evidence: 1) SLC6A3 (DAT) loss of function → DTDS (autosomal recessive; also atypical forms may include dominant-negative mechanisms per review text) (ng2023dopaminetransporterdeficiency pages 1-2, thalib2025acomparativeexploration pages 3-4) 2) DRD1 loss of function (recessive, currently single-family evidence in 2023 report) (reid2023lossoffunctionvariantsin pages 1-2) 3) SLC18A2 (VMAT2) loss of function → PKDYS2/parkinsonism-dystonia-2 (autosomal recessive) (kaasalainen2024novelslc18a2variant pages 1-2, almutair2026casereporttwo pages 2-4)

2.2 Risk factors

Genetic risk factors: biallelic pathogenic variants in the causal genes above; consanguinity is highlighted for the DRD1 case (consanguineous parents) and in PKDYS2 sibling cases. (reid2023lossoffunctionvariantsin pages 6-8, almutair2026casereporttwo pages 2-4)
Environmental risk factors: No specific environmental risk factors were identified in the retrieved evidence for infantile parkinsonism–dystonia as a Mendelian disorder.

2.3 Protective factors / gene–environment interactions

No protective factors or gene–environment interactions were identified in the retrieved evidence.

3. Phenotypes (Clinical Spectrum)

3.1 Core phenotype domains (DTDS-focused)

A 2023 DTDS review describes early-onset nonspecific symptoms evolving to mixed hyper/hypokinetic movement disorder and parkinsonism-dystonia: - Infantile onset features: irritability, feeding difficulties, hypotonia, delayed motor development (ng2023dopaminetransporterdeficiency pages 2-3) - Hyperkinetic movements: chorea, dystonia, ballismus, orolingual dyskinesia (ng2023dopaminetransporterdeficiency pages 2-3) - Progression to parkinsonism-dystonia: dystonic posturing, bradykinesia, tremor, rigidity, akinesia (ng2023dopaminetransporterdeficiency pages 2-3) - Episodic crises: status dystonicus; eye movement disorders including oculogyric crisis (ng2023dopaminetransporterdeficiency pages 2-3)

Age of onset: For DTDS, a comparative review notes typical presentation “within the first 6 months of life.” (thalib2025acomparativeexploration pages 3-4)

3.2 Phenotypes in DRD1-associated infantile parkinsonism-dystonia

The 2023 DRD1 report provides a granular infantile-onset phenotype including: - Global developmental delay with failure of gross motor and vocal milestones (e.g., never sitting/rolling/babbling) (reid2023lossoffunctionvariantsin pages 6-8) - Recurrent generalized dystonia with oculogyric crises (reid2023lossoffunctionvariantsin pages 6-8) - Feeding impairment requiring enteral nutrition; gastrointestinal dysmotility symptoms (reflux/constipation) (reid2023lossoffunctionvariantsin pages 6-8) - Dysautonomia/autonomic-type features: excessive sweating and chronic nasal congestion described (reid2023lossoffunctionvariantsin pages 6-8)

3.3 Phenotypes in SLC18A2 (PKDYS2)

The 2024 PKDYS2 report describes: - Early abnormalities in infancy (first noted at 2 months in the case report) with oculogyric crises, hypotonia, delayed psychomotor development and recurrent generalized dystonic episodes (kaasalainen2024novelslc18a2variant pages 1-2) - Severe functional disability by later childhood with dependence for all activities (kaasalainen2024novelslc18a2variant pages 2-3)

3.4 Suggested HPO terms (based on reported clinical features)

Examples (non-exhaustive; align to the evidence above): - Dystonia (HP:0001332) (ng2023dopaminetransporterdeficiency pages 2-3, reid2023lossoffunctionvariantsin pages 6-8) - Parkinsonism (HP:0001300) (ng2023dopaminetransporterdeficiency pages 2-3) - Bradykinesia (HP:0002067) (ng2023dopaminetransporterdeficiency pages 2-3) - Rigidity (HP:0002063) (ng2023dopaminetransporterdeficiency pages 2-3) - Oculogyric crisis (HP:0002179) (ng2023dopaminetransporterdeficiency pages 2-3, reid2023lossoffunctionvariantsin pages 6-8, kaasalainen2024novelslc18a2variant pages 1-2) - Hypotonia (HP:0001252) (ng2023dopaminetransporterdeficiency pages 2-3, reid2023lossoffunctionvariantsin pages 6-8, kaasalainen2024novelslc18a2variant pages 1-2) - Global developmental delay (HP:0001263) (reid2023lossoffunctionvariantsin pages 1-2, reid2023lossoffunctionvariantsin pages 6-8, kaasalainen2024novelslc18a2variant pages 2-3) - Feeding difficulties (HP:0011968) / Dysphagia (HP:0002015) (ng2023dopaminetransporterdeficiency pages 2-3, reid2023lossoffunctionvariantsin pages 6-8, kaasalainen2024novelslc18a2variant pages 2-3) - Autonomic dysfunction (HP:0002311) / Hyperhidrosis (HP:0000975) (reid2023lossoffunctionvariantsin pages 1-2, reid2023lossoffunctionvariantsin pages 6-8)

3.5 Quality of life impact

The DTDS review notes high care burden (e.g., many require gastrostomy feeding) and severe disability, implying profound quality-of-life impairment for patients and caregivers. (ng2023dopaminetransporterdeficiency pages 2-3)

3.6 Differential diagnosis (high-level, evidence-supported)

DTDS/infantile parkinsonism-dystonia can phenotypically resemble other monoamine neurotransmitter disorders (including disorders of dopamine synthesis/metabolism and vesicular transport). The DRD1 case explicitly notes similarity to monoamine disorders such as AADC deficiency. (reid2023lossoffunctionvariantsin pages 10-12)

4. Genetic / Molecular Information

4.1 Causal genes and inheritance (supported here)

SLC6A3 (DAT): DTDS; primarily biallelic loss-of-function (autosomal recessive), with mention of heterozygous dominant-negative SLC6A3 variants in atypical DTDS in a comparative review. (ng2023dopaminetransporterdeficiency pages 1-2, thalib2025acomparativeexploration pages 3-4)
DRD1 (dopamine receptor D1): homozygous missense c.110C>A (p.T37K) with in vitro loss-of-function in a consanguineous family; proposed as a new disease gene. (reid2023lossoffunctionvariantsin pages 1-2)
SLC18A2 (VMAT2): PKDYS2/parkinsonism-dystonia-2; autosomal recessive. Example variant in 2024 case: NM_003054.4:c.1107dup, p.(Val370Serfs*91). (kaasalainen2024novelslc18a2variant pages 1-2)

4.2 Pathogenic variant classes and functional consequences

SLC6A3 (reviewed in 2023): Pathogenic variants include protein-truncating variants (nonsense, splice-site, deletions) and missense substitutions, with functional consequences including reduced transporter activity, impaired dopamine binding, reduced cell-surface expression, and impaired glycosylation. (ng2023dopaminetransporterdeficiency pages 1-2)

DRD1 p.T37K (2023): In vitro and modeling indicate loss of receptor function (reduced cAMP response; reduced ligand binding). (reid2023lossoffunctionvariantsin pages 1-2, reid2023lossoffunctionvariantsin pages 10-12)

SLC18A2 PKDYS2 (2024): frameshift variant consistent with loss-of-function mechanism; clinical presentation consistent with severe infantile dystonia-parkinsonism. (kaasalainen2024novelslc18a2variant pages 1-2)

4.3 Genotype–phenotype / case counts (DTDS)

The DTDS review summarizes published case numbers: “thirty-one DTDS patients reported in the literature,” plus “a further unpublished twenty patients reported to our centre.” (ng2023dopaminetransporterdeficiency pages 2-3)

5. Environmental Information

No disease-relevant environmental or lifestyle contributors were identified in the retrieved evidence; the disorders discussed are primarily genetic neurotransmitter/transportopathies.

6. Mechanism / Pathophysiology

6.1 DTDS (SLC6A3) mechanistic chain (integrated from multiple evidence sources)

Upstream trigger: loss-of-function in DAT (SLC6A3) reduces dopamine reuptake capacity (ng2023dopaminetransporterdeficiency pages 1-2)

Biochemical consequence (CSF): elevated dopamine catabolism marker HVA with normal 5-HIAA; elevated HVA:5-HIAA ratio (often 5.0–13.0; normal 1.0–4.0). (ng2023dopaminetransporterdeficiency pages 2-3)

Cellular consequences: patient iPSC-derived midbrain dopaminergic neurons show impaired DAT activity with dopamine toxicity, oxidative/carbonyl stress, inflammation-associated apoptosis, and dopaminergic neurodegeneration. (ng2021genetherapyrestores pages 4-6, ng2021genetherapyrestores pages 1-3, ng2021genetherapyrestores pages 17-25)

Circuit/organ consequences: DTDS knockout mice exhibit tremor, bradykinesia, and premature death; gene replacement rescues motor phenotype and neurodegeneration in vivo, supporting a causal link between transporter loss and progressive neurological dysfunction. (ng2021genetherapyrestores pages 1-3, ng2021genetherapyrestores pages 6-8)

6.2 DAT variant mechanism (example: R445C) and “pharmacological rescue” concept

A DTDS-associated DAT substitution R445C disrupts a conserved intracellular gating interaction network, producing compromised transporter function and reduced expression/trafficking; Drosophila expressing hDAT R445C show motor coordination defects, and dietary chloroquine (lysosomal inhibitor) improves a flight-initiation phenotype, consistent with partially restoring DAT maturation/availability. (aguilar2021psychomotorimpairmentsand pages 1-2, aguilar2021psychomotorimpairmentsand pages 14-16)

6.3 DRD1 mechanism

The DRD1 p.T37K variant is predicted and shown to reduce ligand binding and downstream receptor signaling (cAMP response), yielding an infantile parkinsonism–dystonia phenotype despite unexpectedly normal CSF neurotransmitter measures, suggesting postsynaptic dopamine signaling failure can phenocopy presynaptic dopamine deficiency syndromes. (reid2023lossoffunctionvariantsin pages 1-2, reid2023lossoffunctionvariantsin pages 10-12)

6.4 Suggested GO biological process terms (examples)

Dopamine transport (GO:0015872) (aligned to DTDS/SLC6A3 mechanism) (ng2023dopaminetransporterdeficiency pages 1-2)
Dopamine uptake involved in synaptic transmission (GO:0051583) (ng2023dopaminetransporterdeficiency pages 1-2)
Regulation of dopamine secretion (GO:0014043) (relevant to vesicular transport, SLC18A2) (kaasalainen2024novelslc18a2variant pages 1-2)
Neuronal apoptotic process (GO:0051402) (supported by iPSC apoptosis findings) (ng2021genetherapyrestores pages 4-6)
Neuroinflammatory response (GO:0150076) (supported by TNFα-mediated inflammation in iPSC model) (ng2021genetherapyrestores pages 1-3)

6.5 Suggested CL (cell types) and UBERON (anatomy) terms

Cell types (CL): - Midbrain dopaminergic neuron (CL:2000091) (supported by iPSC mDA neuron modeling) (ng2021genetherapyrestores pages 1-3) - Striatal medium spiny neuron (CL:0000540) (electrophysiological/circuit consequences discussed in DTDS models) (ng2021genetherapyrestores pages 8-9)

Anatomy (UBERON): - Substantia nigra (UBERON:0002038) and striatum (UBERON:0002435), targeted/affected in DTDS gene therapy studies (ng2021genetherapyrestores pages 6-8)

7. Anatomical Structures Affected

Evidence from DTDS modeling and therapeutic targeting implicates the nigrostriatal dopaminergic system, including substantia nigra and striatum, as critical affected/targeted structures (demonstrated by targeted AAV2.SLC6A3 delivery to substantia nigra with anterograde transport to striatum and motor rescue). (ng2021genetherapyrestores pages 8-9, ng2021genetherapyrestores pages 6-8)

8. Temporal Development

DTDS onset: typically early infancy; review states presentation “within the first 6 months of life.” (thalib2025acomparativeexploration pages 3-4)
Progression: DTDS is described as progressive with transition from early hyperkinesia to severe childhood parkinsonism-dystonia. (ng2023dopaminetransporterdeficiency pages 2-3)

9. Inheritance and Population

9.1 Inheritance patterns

DTDS: primarily autosomal recessive biallelic SLC6A3 loss-of-function; atypical forms may include dominant-negative mechanisms (as described in a comparative review). (ng2023dopaminetransporterdeficiency pages 1-2, thalib2025acomparativeexploration pages 3-4)
DRD1: autosomal recessive in the reported family (homozygous variant in proband; heterozygous parents). (reid2023lossoffunctionvariantsin pages 6-8)
PKDYS2 (SLC18A2): autosomal recessive. (kaasalainen2024novelslc18a2variant pages 1-2, almutair2026casereporttwo pages 2-4)

9.2 Epidemiology / frequency

DTDS is described as ultrarare; a 2023 review summarizes a published case count (~31 in the literature) plus additional unpublished cases known to a specialist center, and reports deaths in childhood with mean reported age of death 10.4 years (see Prognosis below). (ng2023dopaminetransporterdeficiency pages 2-3)

Robust prevalence/incidence rates were not present in the retrieved evidence.

10. Diagnostics

10.1 Key biochemical and imaging findings (DTDS)

CSF neurotransmitter metabolites: raised HVA with normal 5-HIAA; HVA:5-HIAA ratio typically 5.0–13.0 (normal 1.0–4.0). (ng2023dopaminetransporterdeficiency pages 2-3)
Functional presynaptic dopaminergic imaging: SPECT with 123I-ioflupane (DaTScan) shows “absent or significantly reduced tracer uptake in the basal nuclei” in DTDS. (ng2023dopaminetransporterdeficiency pages 2-3)
Brain MRI: may be normal or show nonspecific abnormalities (e.g., mild delayed myelination, white matter abnormalities, prominence of external frontotemporal spaces). (ng2023dopaminetransporterdeficiency pages 2-3)

10.2 Genetic testing approach

A comparative review states that DTDS diagnosis is confirmed by pathogenic SLC6A3 variants and that the “diagnostic test of choice is a genetic panel such as whole exome sequencing (WES).” (thalib2025acomparativeexploration pages 3-4)

Recent real-world implementation examples: - DRD1 case used trio WGS (30×) and Sanger segregation confirmation. (reid2023lossoffunctionvariantsin pages 2-4) - PKDYS2 case used WES to identify a homozygous SLC18A2 frameshift variant. (kaasalainen2024novelslc18a2variant pages 1-2)

10.3 Differential diagnosis considerations

IPD/DTDS can be confused with other early-onset neurogenetic or neurotransmitter disorders; DRD1 report emphasizes phenotypic similarity to monoamine disorders (e.g., AADC deficiency). (reid2023lossoffunctionvariantsin pages 10-12)

11. Outcome / Prognosis

A 2023 DTDS review reports severe outcomes including childhood death: “eight children have died… mean age of death of 10.4 years.” (ng2023dopaminetransporterdeficiency pages 2-3)

Longitudinal functional outcomes in PKDYS2 include severe disability with need for assistance for all activities (case report by age 9). (kaasalainen2024novelslc18a2variant pages 2-3)

12. Treatment

12.1 Symptomatic pharmacotherapy (DTDS)

The 2023 DTDS review states there is “limited response to standard pharmacotherapies,” with symptomatic approaches including: - tetrabenazine and benzodiazepines for chorea/dyskinesia (ng2023dopaminetransporterdeficiency pages 2-3) - dopamine agonists (e.g., pramipexole, ropinirole) (ng2023dopaminetransporterdeficiency pages 2-3) - gabapentin for stiffness in some cases (ng2023dopaminetransporterdeficiency pages 2-3) - levodopa: “limited or no response to levodopa treatment.” (ng2023dopaminetransporterdeficiency pages 2-3)

MAXO suggestions (examples): - Dopamine agonist therapy (MAXO:0001027) - Levodopa therapy (MAXO:0000746) - Tetrabenazine therapy / monoamine depletion therapy (MAXO term may vary by ontology version; treat as “vesicular monoamine transporter inhibitor therapy”) - Benzodiazepine therapy (MAXO:0000558)

12.2 Treatment response in DRD1 infantile parkinsonism-dystonia

No response to levodopa up to 10 mg/kg/day; dopaminergic therapy ineffective, consistent with in vitro failure of D1 agonists to rescue receptor defect. (reid2023lossoffunctionvariantsin pages 12-13, reid2023lossoffunctionvariantsin pages 6-8)
Modest benefit reported from some tone-modifying agents and transdermal clonidine. (reid2023lossoffunctionvariantsin pages 6-8)

12.3 Treatment response in PKDYS2 (SLC18A2)

The 2024 PKDYS2 case report describes trials including valproate, levodopa-carbidopa, pramipexole, amantadine, methylphenidate with variable/limited benefit and frequent adverse effects; it also notes that levodopa in PKDYS2 “almost always worsens” in prior reports, with dopamine agonists variably beneficial. (kaasalainen2024novelslc18a2variant pages 1-2, kaasalainen2024novelslc18a2variant pages 2-3)

12.4 Advanced therapeutics and experimental approaches (DTDS)

Gene therapy as a major translational direction: - A 2021 Science Translational Medicine study demonstrates that viral gene transfer of wild-type SLC6A3 restores DAT activity and prevents neurodegeneration in patient-derived iPSC midbrain dopaminergic neurons, and that AAV delivery improves motor phenotype, lifespan, and neuronal survival in DTDS mouse models, with dose-related off-target toxicity at high doses and improved safety with targeted midbrain AAV2.SLC6A3 delivery. (Published May 2021; https://doi.org/10.1126/scitranslmed.aaw1564). (ng2021genetherapyrestores pages 1-3, ng2021genetherapyrestores pages 6-8)

Expert/authoritative perspective on translation (2023): A 2023 Movement Disorders review frames a regulatory and translational landscape for dopamine gene therapies, noting approval of Upstaza (AADC deficiency) as an “important land-mark” while emphasizing that “numerous challenges remain,” including defining the “optimal therapeutic window,” durability of effect, and improved brain targeting—issues directly relevant to DTDS translation. (Published May 2023; https://doi.org/10.1002/mds.29416). (ng2023genetherapyfor pages 1-2)

13. Prevention

No primary prevention is applicable for these Mendelian disorders beyond genetic counseling and reproductive options.

Secondary/tertiary prevention concept: early molecular diagnosis (WES/WGS) may reduce diagnostic delay and avoid ineffective treatments; emphasized in PKDYS2 sibling case conclusions and DTDS diagnostic summaries. (almutair2026casereporttwo pages 2-4, thalib2025acomparativeexploration pages 3-4)

14. Other Species / Natural Disease

No naturally occurring (non-experimental) animal disease analogs were identified in the retrieved evidence.

15. Model Organisms

Evidence-supported models include:

1) Patient-derived iPSC midbrain dopaminergic neurons (DTDS/SLC6A3): show impaired DAT activity, apoptotic neurodegeneration, TNFα-mediated inflammation, and dopamine toxicity; enable testing of pharmacochaperones and viral gene replacement. (ng2021genetherapyrestores pages 1-3, ng2021genetherapyrestores pages 17-25)

2) DAT knockout mouse (DTDS/SLC6A3): recapitulates tremor, bradykinesia, and premature death; used for AAV2.SLC6A3 dose-ranging, motor rescue, survival outcomes, and targeting strategy development. (ng2021genetherapyrestores pages 1-3, ng2021genetherapyrestores pages 8-9)

3) Drosophila DAT variant model (hDAT R445C): demonstrates impaired DAT activity, dopamine dysfunction, motor coordination phenotypes (including flight coordination), and pharmacologic rescue by chloroquine via increased DAT maturation/expression. (aguilar2021psychomotorimpairmentsand pages 1-2, aguilar2021psychomotorimpairmentsand pages 14-16)

Recent developments and latest research (prioritizing 2023–2024)

1) New disease gene for infantile parkinsonism-dystonia (DRD1): 2023 Cells report nominates DRD1 as a new disease-associated gene with recessive loss-of-function and severe infantile phenotype, with normal CSF neurotransmitter analysis and poor response to dopaminergic therapy. (Mar 2023; https://doi.org/10.3390/cells12071046). (reid2023lossoffunctionvariantsin pages 1-2, reid2023lossoffunctionvariantsin pages 6-8)

2) DTDS precision medicine framing (2023 Cells review): summarizes expanding phenotype, typical diagnostic findings (CSF ratio, DaTScan), case counts, limited levodopa response, and highlights pharmacochaperones and gene therapy in development. (Jun 2023; https://doi.org/10.3390/cells12131737). (ng2023dopaminetransporterdeficiency pages 2-3)

3) SLC18A2 PKDYS2 case expansion (2024): reports a novel frameshift variant diagnosed via WES with extensive medication trials documenting limited or transient responses and adverse effects. (Apr 2024; https://doi.org/10.1155/2024/4767647). (kaasalainen2024novelslc18a2variant pages 1-2, kaasalainen2024novelslc18a2variant pages 2-3)

4) Gene therapy translation analysis (2023 Movement Disorders): emphasizes therapeutic window, targeting specificity, and durability as key unresolved questions across dopamine gene therapies (relevant to DTDS). (May 2023; https://doi.org/10.1002/mds.29416). (ng2023genetherapyfor pages 1-2, ng2023genetherapyfor pages 9-11)

Summary Table (evidence-backed)

The following table consolidates key Mendelian causes and distinguishing diagnostic/treatment features captured in the retrieved evidence.

Disease label used in papers	Causal gene	Inheritance	Key distinguishing clinical features	Key diagnostic tests/findings	Typical treatment response notes	Key recent references
Dopamine transporter deficiency syndrome (DTDS); infantile parkinsonism-dystonia	SLC6A3	Usually autosomal recessive due to biallelic loss-of-function variants; review also notes heterozygous dominant-negative SLC6A3 variants in atypical DTDS (thalib2025acomparativeexploration pages 3-4, ng2023dopaminetransporterdeficiency pages 1-2)	Infantile onset, often within first 6 months; irritability, feeding difficulties, hypotonia, delayed motor milestones; hyperkinetic movements (chorea, dystonia, ballismus, orolingual dyskinesia) progressing to parkinsonism-dystonia with bradykinesia, tremor, rigidity, akinesia; oculogyric crises/status dystonicus; dysautonomia and severe disability in many cases (ng2023dopaminetransporterdeficiency pages 2-3, thalib2025acomparativeexploration pages 1-3)	CSF: raised HVA with normal 5-HIAA; HVA:5-HIAA ratio typically 5.0–13.0 (normal 1.0–4.0), or practical cutoff >4; DaTScan/SPECT: absent or markedly reduced basal nuclei uptake; MRI may be normal or show mild delayed myelination/white-matter abnormalities/prominent frontotemporal spaces; diagnosis confirmed by WES/gene panel/WGS showing pathogenic SLC6A3 variants (ng2023dopaminetransporterdeficiency pages 2-3, thalib2025acomparativeexploration pages 3-4)	Limited response to standard pharmacotherapy; tetrabenazine and benzodiazepines used for chorea/dyskinesia; dopamine agonists such as pramipexole/ropinirole sometimes used; gabapentin may help stiffness; limited or no response to levodopa; DBS and intrathecal baclofen reported with limited benefit; preclinical gene therapy and pharmacochaperone approaches under development (ng2023dopaminetransporterdeficiency pages 2-3, ng2021genetherapyrestores pages 1-3, ng2023genetherapyfor pages 1-2)	Ng et al., 2023, https://doi.org/10.3390/cells12131737; Ng et al., 2023, https://doi.org/10.1002/mds.29416 (ng2023dopaminetransporterdeficiency pages 2-3, ng2023genetherapyfor pages 1-2)
Infantile parkinsonism-dystonia due to DRD1 loss of function	DRD1	Autosomal recessive in reported case (homozygous variant) (reid2023lossoffunctionvariantsin pages 12-13, reid2023lossoffunctionvariantsin pages 1-2)	Severe infantile parkinsonism-dystonia with frequent oculogyric crises, dysautonomia, global neurodevelopmental impairment; paucity of spontaneous movement, hypomimia, truncal hypotonia with variable limb tone, prolonged generalized dystonia, feeding impairment, reflux, constipation, sweating, chronic nasal congestion; failed to sit/roll/babble (reid2023lossoffunctionvariantsin pages 1-2, reid2023lossoffunctionvariantsin pages 6-8)	Trio WGS identified homozygous DRD1 c.110C>A (p.T37K), absent from gnomAD; CSF neurotransmitters/AADC activity were normal, with slight increase in HVA:5-HIAA noted in supplementary data; MRI referenced in supplementary materials; functional assays showed markedly reduced D1 receptor signaling/ligand binding (reid2023lossoffunctionvariantsin pages 12-13, reid2023lossoffunctionvariantsin pages 1-2, reid2023lossoffunctionvariantsin pages 6-8, reid2023lossoffunctionvariantsin pages 8-10)	No clinical response to levodopa up to 10 mg/kg/day; numerous D1 agonists failed to rescue the cellular defect, matching lack of dopaminergic benefit clinically; modest benefit from some tone-modifying agents and transdermal clonidine reported (reid2023lossoffunctionvariantsin pages 12-13, reid2023lossoffunctionvariantsin pages 6-8, reid2023lossoffunctionvariantsin pages 10-12)	Reid et al., 2023, https://doi.org/10.3390/cells12071046 (reid2023lossoffunctionvariantsin pages 1-2, reid2023lossoffunctionvariantsin pages 12-13)
Infantile dystonia-parkinsonism type 2 (PKDYS2); parkinsonism-dystonia-2; brain dopamine-serotonin vesicular transport disease	SLC18A2	Autosomal recessive (reported homozygous variants) (kaasalainen2024novelslc18a2variant pages 1-2, almutair2026casereporttwo pages 2-4)	Onset in early infancy; global developmental delay, generalized hypotonia, hyperkinetic movements/dystonia, parkinsonism, oculogyric crises, temperature instability/autonomic features, severe speech and motor impairment, feeding/swallowing problems; many remain nonambulatory and dependent for all activities (kaasalainen2024novelslc18a2variant pages 1-2, kaasalainen2024novelslc18a2variant pages 2-3, kaasalainen2024novelslc18a2variant pages 3-4, almutair2026casereporttwo pages 2-4)	WES identified homozygous SLC18A2 variants including frameshift *c.1107dup p.(Val370Serfs91) and splice-site c.1122+2T>C**; EEG may show no epileptiform activity; brain MRI can be unremarkable/normal; CSF testing was planned but not available in one 2026 report (kaasalainen2024novelslc18a2variant pages 1-2, kaasalainen2024novelslc18a2variant pages 2-3, almutair2026casereporttwo pages 2-4)	Levodopa often ineffective or may worsen symptoms; pramipexole can give partial/initial benefit (head support, swallowing, breathing, reduced dystonic episodes) but adverse effects may limit use; valproate mild or unclear benefit; amantadine no clear benefit; methylphenidate may transiently improve alertness/head support but can worsen dystonia/side effects (kaasalainen2024novelslc18a2variant pages 1-2, kaasalainen2024novelslc18a2variant pages 2-3, almutair2026casereporttwo pages 2-4)	Kaasalainen et al., 2024, https://doi.org/10.1155/2024/4767647 (kaasalainen2024novelslc18a2variant pages 1-2, kaasalainen2024novelslc18a2variant pages 2-3)

Table: This table summarizes Mendelian causes discussed in the retrieved evidence for infantile parkinsonism-dystonia and related infantile dystonia-parkinsonism disorders. It compares genes, inheritance, distinguishing clinical features, diagnostic findings, treatment response patterns, and recent references supported by the available evidence snippets.

Limitations of this report (due to available tool evidence)

Several required identifiers (MONDO, Orphanet, MeSH, ICD codes) and population-level prevalence/incidence were not present in the retrieved full-text snippets; they are therefore not reported to avoid uncited or inaccurate assertions.
Many classic DTDS primary series (e.g., earliest cohorts) are referenced within reviews but were not directly available as full text in the retrieved evidence set for direct PMID-quoting.

References

(ng2023dopaminetransporterdeficiency pages 2-3): Joanne Ng, Serena Barral, Simon N. Waddington, and Manju A. Kurian. Dopamine transporter deficiency syndrome (dtds): expanding the clinical phenotype and precision medicine approaches. Cells, 12:1737, Jun 2023. URL: https://doi.org/10.3390/cells12131737, doi:10.3390/cells12131737. This article has 27 citations.
(ng2023dopaminetransporterdeficiency pages 1-2): Joanne Ng, Serena Barral, Simon N. Waddington, and Manju A. Kurian. Dopamine transporter deficiency syndrome (dtds): expanding the clinical phenotype and precision medicine approaches. Cells, 12:1737, Jun 2023. URL: https://doi.org/10.3390/cells12131737, doi:10.3390/cells12131737. This article has 27 citations.
(reid2023lossoffunctionvariantsin pages 1-2): Genomics England Research, Kimberley M Reid, D. Steel, Sanjana Nair, S. Bhate, L. Biassoni, S. Sudhakar, M. Heys, Elizabeth A Burke, E. Kamsteeg, Genomics England, Research Consortium, B. Hameed, M. Zech, N. Mencacci, Katy Barwick, M. Topf, and M. Kurian. Loss-of-function variants in drd1 in infantile parkinsonism-dystonia. Cells, 12:1046, Mar 2023. URL: https://doi.org/10.3390/cells12071046, doi:10.3390/cells12071046. This article has 15 citations.
(kaasalainen2024novelslc18a2variant pages 1-2): Sakari Kaasalainen, Harri Arikka, Mika H. Martikainen, and Valtteri Kaasinen. Novel slc18a2 variant in infantile dystonia-parkinsonism type 2. Case Reports in Neurological Medicine, Apr 2024. URL: https://doi.org/10.1155/2024/4767647, doi:10.1155/2024/4767647. This article has 3 citations and is from a peer-reviewed journal.
(almutair2026casereporttwo pages 2-4): Meshal Almutair and Wejdan S. Hakami. Case report: two siblings with a novel homozygous slc18a2 variant causing parkinsonism-dystonia-2: a case series from saudi arabia. Frontiers in Genetics, May 2026. URL: https://doi.org/10.3389/fgene.2026.1812336, doi:10.3389/fgene.2026.1812336. This article has 0 citations and is from a peer-reviewed journal.
(ng2021genetherapyrestores pages 1-3): Joanne Ng, Serena Barral, Carmen De La Fuente Barrigon, Gabriele Lignani, Fatma A. Erdem, Rebecca Wallings, Riccardo Privolizzi, Giada Rossignoli, Haya Alrashidi, Sonja Heasman, Esther Meyer, Adeline Ngoh, Simon Pope, Rajvinder Karda, Dany Perocheau, Julien Baruteau, Natalie Suff, Juan Antinao Diaz, Stephanie Schorge, Jane Vowles, Lucy R. Marshall, Sally A. Cowley, Sonja Sucic, Michael Freissmuth, John R. Counsell, Richard Wade-Martins, Simon J. R. Heales, Ahad A. Rahim, Maximilien Bencze, Simon N. Waddington, and Manju A. Kurian. Gene therapy restores dopamine transporter expression and ameliorates pathology in ipsc and mouse models of infantile parkinsonism. Science Translational Medicine, May 2021. URL: https://doi.org/10.1126/scitranslmed.aaw1564, doi:10.1126/scitranslmed.aaw1564. This article has 59 citations and is from a highest quality peer-reviewed journal.
(aguilar2021psychomotorimpairmentsand pages 1-2): Jenny I Aguilar, Mary Hongying Cheng, Josep Font, Alexandra C Schwartz, Kaitlyn Ledwitch, Amanda Duran, Samuel J Mabry, Andrea N Belovich, Yanqi Zhu, Angela M Carter, Lei Shi, Manju A Kurian, Cristina Fenollar-Ferrer, Jens Meiler, Renae Monique Ryan, Hassane S Mchaourab, Ivet Bahar, Heinrich JG Matthies, and Aurelio Galli. Psychomotor impairments and therapeutic implications revealed by a mutation associated with infantile parkinsonism-dystonia. May 2021. URL: https://doi.org/10.7554/elife.68039, doi:10.7554/elife.68039. This article has 24 citations and is from a domain leading peer-reviewed journal.
(kaasalainen2024novelslc18a2variant pages 2-3): Sakari Kaasalainen, Harri Arikka, Mika H. Martikainen, and Valtteri Kaasinen. Novel slc18a2 variant in infantile dystonia-parkinsonism type 2. Case Reports in Neurological Medicine, Apr 2024. URL: https://doi.org/10.1155/2024/4767647, doi:10.1155/2024/4767647. This article has 3 citations and is from a peer-reviewed journal.
(thalib2025acomparativeexploration pages 3-4): Husna Irfan Thalib, Rand Redwan Al Sari, Syeda Sobiah Imad, Sariya Khan, Shyma Haidar, Bayan Mohammed Khair Al Zoabi, Sahar Hamed Fadda, Samratul Fuadah, Hassan Abu Alwan, and Abdullah Alghobaishi. A comparative exploration of monoamine neurotransmitter transport disorders: mechanisms, clinical manifestations, and therapeutic approaches. Journal of Medicine and Life, 18:188-195, Mar 2025. URL: https://doi.org/10.25122/jml-2024-0398, doi:10.25122/jml-2024-0398. This article has 3 citations.
(reid2023lossoffunctionvariantsin pages 6-8): Genomics England Research, Kimberley M Reid, D. Steel, Sanjana Nair, S. Bhate, L. Biassoni, S. Sudhakar, M. Heys, Elizabeth A Burke, E. Kamsteeg, Genomics England, Research Consortium, B. Hameed, M. Zech, N. Mencacci, Katy Barwick, M. Topf, and M. Kurian. Loss-of-function variants in drd1 in infantile parkinsonism-dystonia. Cells, 12:1046, Mar 2023. URL: https://doi.org/10.3390/cells12071046, doi:10.3390/cells12071046. This article has 15 citations.
(reid2023lossoffunctionvariantsin pages 10-12): Genomics England Research, Kimberley M Reid, D. Steel, Sanjana Nair, S. Bhate, L. Biassoni, S. Sudhakar, M. Heys, Elizabeth A Burke, E. Kamsteeg, Genomics England, Research Consortium, B. Hameed, M. Zech, N. Mencacci, Katy Barwick, M. Topf, and M. Kurian. Loss-of-function variants in drd1 in infantile parkinsonism-dystonia. Cells, 12:1046, Mar 2023. URL: https://doi.org/10.3390/cells12071046, doi:10.3390/cells12071046. This article has 15 citations.
(ng2021genetherapyrestores pages 4-6): Joanne Ng, Serena Barral, Carmen De La Fuente Barrigon, Gabriele Lignani, Fatma A. Erdem, Rebecca Wallings, Riccardo Privolizzi, Giada Rossignoli, Haya Alrashidi, Sonja Heasman, Esther Meyer, Adeline Ngoh, Simon Pope, Rajvinder Karda, Dany Perocheau, Julien Baruteau, Natalie Suff, Juan Antinao Diaz, Stephanie Schorge, Jane Vowles, Lucy R. Marshall, Sally A. Cowley, Sonja Sucic, Michael Freissmuth, John R. Counsell, Richard Wade-Martins, Simon J. R. Heales, Ahad A. Rahim, Maximilien Bencze, Simon N. Waddington, and Manju A. Kurian. Gene therapy restores dopamine transporter expression and ameliorates pathology in ipsc and mouse models of infantile parkinsonism. Science Translational Medicine, May 2021. URL: https://doi.org/10.1126/scitranslmed.aaw1564, doi:10.1126/scitranslmed.aaw1564. This article has 59 citations and is from a highest quality peer-reviewed journal.
(ng2021genetherapyrestores pages 17-25): Joanne Ng, Serena Barral, Carmen De La Fuente Barrigon, Gabriele Lignani, Fatma A. Erdem, Rebecca Wallings, Riccardo Privolizzi, Giada Rossignoli, Haya Alrashidi, Sonja Heasman, Esther Meyer, Adeline Ngoh, Simon Pope, Rajvinder Karda, Dany Perocheau, Julien Baruteau, Natalie Suff, Juan Antinao Diaz, Stephanie Schorge, Jane Vowles, Lucy R. Marshall, Sally A. Cowley, Sonja Sucic, Michael Freissmuth, John R. Counsell, Richard Wade-Martins, Simon J. R. Heales, Ahad A. Rahim, Maximilien Bencze, Simon N. Waddington, and Manju A. Kurian. Gene therapy restores dopamine transporter expression and ameliorates pathology in ipsc and mouse models of infantile parkinsonism. Science Translational Medicine, May 2021. URL: https://doi.org/10.1126/scitranslmed.aaw1564, doi:10.1126/scitranslmed.aaw1564. This article has 59 citations and is from a highest quality peer-reviewed journal.
(ng2021genetherapyrestores pages 6-8): Joanne Ng, Serena Barral, Carmen De La Fuente Barrigon, Gabriele Lignani, Fatma A. Erdem, Rebecca Wallings, Riccardo Privolizzi, Giada Rossignoli, Haya Alrashidi, Sonja Heasman, Esther Meyer, Adeline Ngoh, Simon Pope, Rajvinder Karda, Dany Perocheau, Julien Baruteau, Natalie Suff, Juan Antinao Diaz, Stephanie Schorge, Jane Vowles, Lucy R. Marshall, Sally A. Cowley, Sonja Sucic, Michael Freissmuth, John R. Counsell, Richard Wade-Martins, Simon J. R. Heales, Ahad A. Rahim, Maximilien Bencze, Simon N. Waddington, and Manju A. Kurian. Gene therapy restores dopamine transporter expression and ameliorates pathology in ipsc and mouse models of infantile parkinsonism. Science Translational Medicine, May 2021. URL: https://doi.org/10.1126/scitranslmed.aaw1564, doi:10.1126/scitranslmed.aaw1564. This article has 59 citations and is from a highest quality peer-reviewed journal.
(aguilar2021psychomotorimpairmentsand pages 14-16): Jenny I Aguilar, Mary Hongying Cheng, Josep Font, Alexandra C Schwartz, Kaitlyn Ledwitch, Amanda Duran, Samuel J Mabry, Andrea N Belovich, Yanqi Zhu, Angela M Carter, Lei Shi, Manju A Kurian, Cristina Fenollar-Ferrer, Jens Meiler, Renae Monique Ryan, Hassane S Mchaourab, Ivet Bahar, Heinrich JG Matthies, and Aurelio Galli. Psychomotor impairments and therapeutic implications revealed by a mutation associated with infantile parkinsonism-dystonia. May 2021. URL: https://doi.org/10.7554/elife.68039, doi:10.7554/elife.68039. This article has 24 citations and is from a domain leading peer-reviewed journal.
(ng2021genetherapyrestores pages 8-9): Joanne Ng, Serena Barral, Carmen De La Fuente Barrigon, Gabriele Lignani, Fatma A. Erdem, Rebecca Wallings, Riccardo Privolizzi, Giada Rossignoli, Haya Alrashidi, Sonja Heasman, Esther Meyer, Adeline Ngoh, Simon Pope, Rajvinder Karda, Dany Perocheau, Julien Baruteau, Natalie Suff, Juan Antinao Diaz, Stephanie Schorge, Jane Vowles, Lucy R. Marshall, Sally A. Cowley, Sonja Sucic, Michael Freissmuth, John R. Counsell, Richard Wade-Martins, Simon J. R. Heales, Ahad A. Rahim, Maximilien Bencze, Simon N. Waddington, and Manju A. Kurian. Gene therapy restores dopamine transporter expression and ameliorates pathology in ipsc and mouse models of infantile parkinsonism. Science Translational Medicine, May 2021. URL: https://doi.org/10.1126/scitranslmed.aaw1564, doi:10.1126/scitranslmed.aaw1564. This article has 59 citations and is from a highest quality peer-reviewed journal.
(reid2023lossoffunctionvariantsin pages 2-4): Genomics England Research, Kimberley M Reid, D. Steel, Sanjana Nair, S. Bhate, L. Biassoni, S. Sudhakar, M. Heys, Elizabeth A Burke, E. Kamsteeg, Genomics England, Research Consortium, B. Hameed, M. Zech, N. Mencacci, Katy Barwick, M. Topf, and M. Kurian. Loss-of-function variants in drd1 in infantile parkinsonism-dystonia. Cells, 12:1046, Mar 2023. URL: https://doi.org/10.3390/cells12071046, doi:10.3390/cells12071046. This article has 15 citations.
(reid2023lossoffunctionvariantsin pages 12-13): Genomics England Research, Kimberley M Reid, D. Steel, Sanjana Nair, S. Bhate, L. Biassoni, S. Sudhakar, M. Heys, Elizabeth A Burke, E. Kamsteeg, Genomics England, Research Consortium, B. Hameed, M. Zech, N. Mencacci, Katy Barwick, M. Topf, and M. Kurian. Loss-of-function variants in drd1 in infantile parkinsonism-dystonia. Cells, 12:1046, Mar 2023. URL: https://doi.org/10.3390/cells12071046, doi:10.3390/cells12071046. This article has 15 citations.
(ng2023genetherapyfor pages 1-2): Joanne Ng, Serena Barral, Simon N. Waddington, and Manju A. Kurian. Gene therapy for dopamine dyshomeostasis: from parkinson's to primary neurotransmitter diseases. Movement Disorders, 38:924-936, May 2023. URL: https://doi.org/10.1002/mds.29416, doi:10.1002/mds.29416. This article has 23 citations and is from a highest quality peer-reviewed journal.
(ng2023genetherapyfor pages 9-11): Joanne Ng, Serena Barral, Simon N. Waddington, and Manju A. Kurian. Gene therapy for dopamine dyshomeostasis: from parkinson's to primary neurotransmitter diseases. Movement Disorders, 38:924-936, May 2023. URL: https://doi.org/10.1002/mds.29416, doi:10.1002/mds.29416. This article has 23 citations and is from a highest quality peer-reviewed journal.
(thalib2025acomparativeexploration pages 1-3): Husna Irfan Thalib, Rand Redwan Al Sari, Syeda Sobiah Imad, Sariya Khan, Shyma Haidar, Bayan Mohammed Khair Al Zoabi, Sahar Hamed Fadda, Samratul Fuadah, Hassan Abu Alwan, and Abdullah Alghobaishi. A comparative exploration of monoamine neurotransmitter transport disorders: mechanisms, clinical manifestations, and therapeutic approaches. Journal of Medicine and Life, 18:188-195, Mar 2025. URL: https://doi.org/10.25122/jml-2024-0398, doi:10.25122/jml-2024-0398. This article has 3 citations.
(reid2023lossoffunctionvariantsin pages 8-10): Genomics England Research, Kimberley M Reid, D. Steel, Sanjana Nair, S. Bhate, L. Biassoni, S. Sudhakar, M. Heys, Elizabeth A Burke, E. Kamsteeg, Genomics England, Research Consortium, B. Hameed, M. Zech, N. Mencacci, Katy Barwick, M. Topf, and M. Kurian. Loss-of-function variants in drd1 in infantile parkinsonism-dystonia. Cells, 12:1046, Mar 2023. URL: https://doi.org/10.3390/cells12071046, doi:10.3390/cells12071046. This article has 15 citations.
(kaasalainen2024novelslc18a2variant pages 3-4): Sakari Kaasalainen, Harri Arikka, Mika H. Martikainen, and Valtteri Kaasinen. Novel slc18a2 variant in infantile dystonia-parkinsonism type 2. Case Reports in Neurological Medicine, Apr 2024. URL: https://doi.org/10.1155/2024/4767647, doi:10.1155/2024/4767647. This article has 3 citations and is from a peer-reviewed journal.

Artifacts

Edison artifact artifact-00

Ask OpenScientist

OpenScientist Report

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Source YAML

References & Deep Research

References

Deep Research

1. Disease Information (Overview)

2. Etiology

2.1 Disease causal factors (primary)

2.2 Risk factors

2.3 Protective factors / gene–environment interactions

3. Phenotypes (Clinical Spectrum)

3.1 Core phenotype domains (DTDS-focused)

3.2 Phenotypes in DRD1-associated infantile parkinsonism-dystonia

3.3 Phenotypes in SLC18A2 (PKDYS2)

3.4 Suggested HPO terms (based on reported clinical features)

3.5 Quality of life impact

3.6 Differential diagnosis (high-level, evidence-supported)

4. Genetic / Molecular Information

4.1 Causal genes and inheritance (supported here)

4.2 Pathogenic variant classes and functional consequences

4.3 Genotype–phenotype / case counts (DTDS)

5. Environmental Information

6. Mechanism / Pathophysiology

6.1 DTDS (SLC6A3) mechanistic chain (integrated from multiple evidence sources)

6.2 DAT variant mechanism (example: R445C) and “pharmacological rescue” concept

6.3 DRD1 mechanism

6.4 Suggested GO biological process terms (examples)

6.5 Suggested CL (cell types) and UBERON (anatomy) terms

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

9.1 Inheritance patterns

9.2 Epidemiology / frequency

10. Diagnostics

10.1 Key biochemical and imaging findings (DTDS)

10.2 Genetic testing approach

10.3 Differential diagnosis considerations

11. Outcome / Prognosis

12. Treatment

12.1 Symptomatic pharmacotherapy (DTDS)

12.2 Treatment response in DRD1 infantile parkinsonism-dystonia

12.3 Treatment response in PKDYS2 (SLC18A2)

12.4 Advanced therapeutics and experimental approaches (DTDS)

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Recent developments and latest research (prioritizing 2023–2024)

Summary Table (evidence-backed)

Limitations of this report (due to available tool evidence)

Artifacts